Summary

Mild Cognitive Impairment Market Research Report By Disease Type (Amnestic MCI and Non-Amnestic MCI), By Age (Child, Adult, Geriatric), By Indication (Lewy Body Dementia, Parkinson’s Disease Dementia, Alzheimer’s Disease, Vascular Dementia, and Others) By Treatment (Medication (Cholinesterase Inhibitors, Benzodiazepines, Glutamate Inhibitors, Antihistamines, Mao Inhibitors, Proton Pump Inhibitors, and Others), Therapy (Cognitive Stimulation Therapy, Cognitive Behavioural Therapy (CBT)), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World - Forecast Till 2032

Market Overview
In 2023, the market size for mild cognitive impairment was estimated to be USD 1.94 billion. During the forecast period (2024-2032), the Global Mild Cognitive Impairment industry is anticipated to experience a compound annual growth rate (CAGR) of 5.95%, increasing from USD 2.05 Billion in 2024 to USD 3.25 Billion by 2032.
The growth of the Mild Cognitive Impairment Market is primarily driven by the rising awareness of mild cognitive impairment and the increasing prevalence of the condition worldwide. Nevertheless, the global market's expansion is anticipated to be impeded by the complexity of treatment strategies and polypharmacy, as well as the management of comorbidities. However, it is anticipated that the market will generate profitable opportunities as a result of technological advancements in the early diagnosis of MCI on a global scale. The global MCI treatment market is experiencing substantial growth due to the growing prevalence of moderate cognitive impairment (MCI) on a global scale.

Market Segmentation
Segmentation of the Mild Cognitive Impairment Market by disease type, including amnestic MCI and non-amnestic MCI..
The mild cognitive impairment market segmentation is distinguished by age, consisting of infant, adult, and geriatric segments.
The Mild Cognitive Impairment Market has been segmented by indication into Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and others.
Medication and therapy comprise the Mild Cognitive Impairment Market.

Regional Perspectives
The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. The mild cognitive impairment market in North America held the largest market share of 42.60% in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.97% during the forecast period, reaching an estimated USD 01.31 billion by 2032. Nevertheless, the Asia-Pacific region is expected to experience the most significant compound annual growth rate (CAGR) of 6.91% during the forecast period. The mild cognitive impairment market in North America is expected to experience sustained growth, which is a promising development. It is anticipated that the market will continue to expand due to investments in healthcare infrastructure and an increasing awareness of advanced medical solutions. Both established companies and emerging entrants are prepared to capitalize on these opportunities by utilizing technological advancements to satisfy the increasing demand for enhanced surgical outcomes.
The European mild cognitive impairment market accounted for the second-largest market share because of the increasing burden of mild cognitive impairment, increasing healthcare expenditure, and technological advancements. Furthermore, the mild cognitive impairment market in Germany is believed to have the largest market share, while the mild cognitive impairment market in the United Kingdom is expected to experience the quickest growth in the European region.

Due to the high patient population, the increasing number of mild cognitive impairment cases, and favorable regulatory policies, the Asia-Pacific mild cognitive impairment market is anticipated to experience the most rapid growth from 2024 to 2032. Furthermore, this region is experiencing growth due to the active expansion of key participants in the mild cognitive impairment market. Additionally, the mild cognitive impairment market in China is expected to have the highest market share, while the market in India is expected to experience the quickest growth in the Asia-Pacific region.

Major Players
Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), AbbVie Inc. (US), Biogen (Switzerland), Eisai Co., Ltd. (Japan), Aurobindo Pharma (India), Sun Pharmaceutical Industries Ltd (India), Teva Pharmaceutical Industries Ltd. (Israel), and Taj Pharmaceuticals Limited (India) are the key companies in the mild cognitive impairment market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
3.5.1 Primary Research DATA FLOW:
3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
3.7.1 Data forecasting Technique
3.8 DATA MODELLING
3.8.1 Microeconomic Factor Analysis:
3.8.2 Data MODELLING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 Increasing burden of Mild cognitive impairment across the globe
4.2.2 Rising awareness associated with mild cognitive impairment
4.3 RESTRAINTS
4.3.1 Polypharmacy and managing comorbidities complicate treatment strategies
4.4 OPPORTUNITY
4.4.1 Technological advancements for early diagnosis of MCI
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 Threat of New Entrants
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 Threat of Substitutes
5.1.4 Bargaining Power of Buyers
5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GLOBAL MILD COGNITIVE IMPAIRMENT MARKET
6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE
6.1 OVERVIEW
6.2 AMNESTIC MCI
6.3 NON-AMNESTIC MCI
7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE
7.1 OVERVIEW
7.2 CHILD
7.3 ADULT
7.4 GERIATRIC
8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION
8.1 OVERVIEW
8.2 LEWY BODY DEMENTIA
8.3 PARKINSON'S DISEASE DEMENTIA
8.4 ALZHEIMER’S DISEASE
8.5 VASCULAR DEMENTIA
8.6 OTHERS
9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT
9.1 OVERVIEW
9.2 MEDICATION
9.2.1 Cholinesterase Inhibitors
9.2.2 Benzodiazepines
9.2.3 Glutamate Inhibitors
9.2.4 Antihistamines
9.2.5 Mao Inhibitors
9.2.6 Proton Pump Inhibitors
9.2.7 Others
9.3 THERAPY
9.3.1 Cognitive Stimulation Therapy
9.3.2 Cognitive Behavioural Therapy (CBT)
10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 us
10.2.2 canada
10.3 EUROPE
10.3.1 Germany
10.3.2 France
10.3.3 UK
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 ASIA-PACIFIC
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 South Korea
10.4.5 AUSTRALIA
10.4.6 Rest of Asia-Pacific
10.5 REST OF THE WORLD
10.5.1 Middle East & Africa
10.5.2 Latin America
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2022
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 product launch / Product approval
12 COMPANY PROFILES
12.1 JOHNSON & JOHNSON SERVICES, INC
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 productS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 PFIZER INC
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 productS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 NOVARTIS AG
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 productS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 ABBVIE INC.
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 BIOGEN
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIES
12.6 EISAI CO., LTD.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 AUROBINDO PHARMA
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIES
12.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 TAJ PHARMACEUTICALS LTD.
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
13 DATA CITATIONS